Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TNYA
TNYA logo

TNYA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Tenaya Therapeutics Inc (TNYA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.790
1 Day change
5.50%
52 Week Range
2.350
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Tenaya Therapeutics Inc (TNYA) is not a strong buy at the moment for a beginner, long-term investor. The lack of positive trading signals, insider selling trends, and bearish technical indicators suggest that this stock does not currently present a solid entry point. Additionally, there are no recent positive catalysts or financial data to support a buy decision.

Technical Analysis

The technical indicators show a bearish trend with the MACD below 0 and negatively contracting, RSI in the neutral zone at 51.596, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are at Pivot: 0.715, R1: 0.747, and S1: 0.682. The stock is trading near its resistance level, with no clear upward momentum.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
7

Positive Catalysts

  • NULL identified. There is no recent news or significant positive developments.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 55373.56% increase in selling over the last month. No recent congress trading data or influential figure activity. The stock has a bearish technical setup and lacks upward momentum.

Financial Performance

No financial data is available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for TNYA.

Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
Wall Street analysts forecast TNYA stock price to rise
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.746
sliders
Low
2
Averages
9.14
High
40
Current: 0.746
sliders
Low
2
Averages
9.14
High
40
Morgan Stanley
Overweight
downgrade
$5 -> $2
AI Analysis
2026-01-08
Reason
Morgan Stanley
Price Target
$5 -> $2
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Tenaya Therapeutics to $2 from $5 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Canaccord
Buy
downgrade
$6 -> $4
2025-12-18
Reason
Canaccord
Price Target
$6 -> $4
2025-12-18
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Tenaya Therapeutics to $4 from $6 and keeps a Buy rating on the shares. The firm two key updates from the company; the lifting of the clinical hold on the MyPEAK-1 trial of TN-201 by the FDA and the first look at interim data from the RIDGE-1 Ph1B clinical trial of TN-401 for PKP2-associated ARVC.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TNYA
Unlock Now

People Also Watch